ERBB2 and ductal breast carcinoma in situ: This corresponded to a significantly higher frequency of AAbs to each of the following six TAAs: p53, c-myc, HER2, NY-ESO-1, BRCA2, and MUC1, in breast carcinoma patients compared to controls and in ductal carcinoma in situ patients compared to controls.